ICER Indefinitely Postpones Public Meetings for Sickle Cell Disease and Cystic Fibrosis; Expands Other Assessment Timelines Up to Three Months

This perspective was first shared in our Weekly View e-newsletter, which summarizes the week’s most significant drug pricing news. To subscribe, click here

Priorities: ICER announced this week that we are indefinitely postponing our public meetings for sickle cell disease and cystic fibrosis. We are also pausing all other reviews for up to three months.

Our process involves significant engagement across a variety of external stakeholders — health care providers, life sciences companies, health insurers, and patient advocates — the same individuals who are on the front lines of preparing for and responding to the COVID-19 pandemic. We hope our expanded timelines will enable all stakeholders to instead focus on meeting the needs of their patient communities during this national emergency. And we thank them for their service.

Our decision was covered by Reuters, Endpoints News, and S&P Global.